FA
RXRX icon

FDx Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

FDx Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-23,299
Closed -$230K – 584
2023
Q4 		$230K Buy
+23,299
New +$166K 0.02% 616

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FDx Advisors's RXRX Position: Q1 2024 in Review

FDx Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q1 2024, closing a stake of 23,299 shares — an estimated $230K sold.

FDx Advisors first reported a position in RXRX in Q4 2023 and held it in 1 quarter. The position peaked at $230K in Q4 2023. 249 funds tracked by Wall St. Rank hold RXRX as of Q1 2024.

  • FDx Advisors reported no remaining Recursion Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • FDx Advisors sold 23,299 Recursion Pharmaceuticals shares in Q1 2024, an estimated $230K.
  • FDx Advisors first reported a position in Recursion Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • FDx Advisors's Recursion Pharmaceuticals position peaked at $230K in Q4 2023.
  • 249 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2024.

Based on FDx Advisors's 13F filing for Q1 2024, filed 3 May 2024.